Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

WuXi XDC Partners with BioDlink International for Monoclonal Antibody Intermediate Manufacturing in RMB 190 Million CRDMO Agreement

Fineline Cube Jun 17, 2026
Company Deals

Servier Group Partners with n-Lorem Foundation to Develop ASO Therapies for Rare Neurodevelopmental Disorders

Fineline Cube Jun 17, 2026
Company Deals

Shanghai Juncell Therapeutics Files for HKEX Listing with Breakthrough TIL Therapy GC101 for Solid Tumors

Fineline Cube Jun 17, 2026
Company Deals

Everest Medicines Licenses DMX-200 from Dimerix – CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets

Fineline Cube Jun 16, 2026
Company Deals

Harbour BioMed and BioMap Launch MegaStream TechBio – Next-Generation AI Drug Discovery Company Targeting Global Markets

Fineline Cube Jun 16, 2026
Policy / Regulatory

NMPA Releases 106th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Including BeOne Medicines’ Brukinsa (zanubrutinib)

Fineline Cube Jun 17, 2026
Company Drug

Walvax Biotechnology’s 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial

Fineline Cube Jun 17, 2026
Company Drug

Insilico Medicine’s NLRP3 Inhibitor ISM8969 Achieves First-in-Human Milestone in Phase I Trial for CNS Disorders

Fineline Cube Jun 17, 2026
Company Drug

Chia Tai Tianqing Presents Positive Phase II Data for TQC2938 in Allergic Rhinitis – Novel ST2-Targeting mAb Shows Efficacy Across Inflammatory Pathways

Fineline Cube Jun 16, 2026

Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Limited (HKG:...

Company Deals

Harbour BioMed and BioMap Launch MegaStream TechBio – Next-Generation AI Drug Discovery Company Targeting Global Markets

Fineline Cube Jun 16, 2026

Harbour BioMed (HKG: 2142) announced it will co-establish, together with U.S. biotechnology company BioMap, a...

Company Drug

BMS Secures NMPA Approval for Sotyktu in Psoriatic Arthritis – First Selective TYK2 Inhibitor Expands China Indications

Fineline Cube Jun 16, 2026

Bristol-Myers Squibb (BMS, NYSE: BMY) announced that China’s National Medical Products Administration (NMPA) has granted...

Others

Lonza and Antharis Therapeutics Forge Exclusive ADC Partnership – Dual-Payload Platform Targets Gastrointestinal Cancers

Fineline Cube Jun 16, 2026

Lonza Group Ltd. (SWX: LONN) and Antharis Therapeutics announced on June 15, 2026, an exclusive,...

Company Deals

AstraZeneca Joins ZERO Prostate Cancer’s Blitz the Barriers Initiative – Ambitious Program Aims to Save 100,000 Lives by 2035

Fineline Cube Jun 16, 2026

ZERO Prostate Cancer, the leading prostate cancer organization in the United States, announced on June...

Company Drug

Gilead Sciences Submits sNDA for Once-Weekly Oral Yeztugo PrEP – Potential First Long-Acting Oral HIV Prevention Option

Fineline Cube Jun 16, 2026

Gilead Sciences, Inc. (NASDAQ: GILD) announced that the U.S. Food and Drug Administration (FDA) has...

Company Deals

Johnson & Johnson Invests $1 Billion in Jacksonville Vision Facility – Expands ACUVUE Manufacturing and Distribution

Fineline Cube Jun 16, 2026

Johnson & Johnson (J&J, NYSE: JNJ) announced a $1+ billion investment in Jacksonville, Florida, to...

Company Deals

Lynk Pharmaceuticals Files for Hong Kong IPO – Autoimmune Pipeline Led by JAK Inhibitors and Novel Protein Degraders

Fineline Cube Jun 16, 2026

Lynk Pharmaceuticals Co., Ltd. announced it has published its prospectus and formally applied for listing...

Others

Bayer Secures FDA Approval for Ambelvist – Novel High-Relaxivity MRI Contrast Agent with Lower Gadolinium Dose

Fineline Cube Jun 16, 2026

Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration (FDA) has granted...

Company Drug

Shanghai Leadingtac Secures NMPA Approval for LT-010391 – China’s First Clinical-Stage Oral KRAS-G12D Degrader

Fineline Cube Jun 16, 2026

Shanghai Leadingtac Pharmaceutical Co., Ltd. announced that China’s National Medical Products Administration (NMPA) has granted...

Company Drug

Fosun Pharma Secures NMPA Approval for Fumaining in Pediatric Langerhans Cell Histiocytosis – Expands MEK Inhibitor Franchise

Fineline Cube Jun 16, 2026

Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196; HKG: 2196) announced that China’s National Medical Products...

Company Deals

TriApex Laboratories Files for Hong Kong IPO – Next-Generation CRO with 240+ NMPA Approvals

Fineline Cube Jun 16, 2026

TriApex Laboratories Co., Ltd. announced it has published its prospectus and formally applied for listing...

Company Deals

Ningbo Sanxing Medical Electric Files HKEX Prospectus with Dual Business Model in Power Equipment and Rehabilitation Services

Fineline Cube Jun 15, 2026

Ningbo Sanxing Medical Electric Co., Ltd. announced it has filed its prospectus for listing on...

Company Drug

Gritpharma Secures NMPA Approval for Doxylamine as China’s First Novel Short-Term Insomnia Treatment

Fineline Cube Jun 15, 2026

Nanjing Gritpharma Co., Ltd. announced it has received marketing approval from China’s National Medical Products...

Company Deals Hospital Medical Device

Baheal Pharma Partners with Jinan Junxin Hospital to Launch ZAP-X Precision Radiosurgery Center

Fineline Cube Jun 15, 2026

Baheal Pharma Group (SHE: 301015) announced a strategic partnership with Jinan Junxin Cancer Hospital to...

Company Deals

Lannacheng Biotechnology Files HKEX Prospectus with 13-Candidate Radiopharmaceutical Pipeline

Fineline Cube Jun 15, 2026

Yantai Lannacheng Biotechnology Co., Ltd. announced it has filed its prospectus for listing on the...

Company Legal / IP

Harbour BioMed Wins $20.2 Million Patent Verdict Against Amgen in Delaware Court

Fineline Cube Jun 15, 2026

Harbour BioMed (HKG: 2142) announced that a jury in the U.S. District Court for the...

Company Drug

Sichuan Biokin’s Iza-Bren Becomes World’s First EGFR×HER3 Bispecific ADC with NDA Accepted by China’s NMPA

Fineline Cube Jun 15, 2026

Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that the new drug application (NDA) for...

Company Deals

SSY Group Secures Exclusive China License for OPT101, Novel Peritoneal Dialysis Therapy from Opterion Health

Fineline Cube Jun 15, 2026

SSY Group Limited (HKG: 2005) announced it has entered into a letter of intent with...

Company Deals

Simcere Pharmaceutical Partners with Stanford University to Develop First-in-Class IPF Therapy

Fineline Cube Jun 15, 2026

Simcere Pharmaceutical Group (HKG: 2096) announced a collaborative research agreement with Stanford University School of...

Posts pagination

1 2 3 … 685

Recent updates

  • Walvax Biotechnology’s 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial
  • Insilico Medicine’s NLRP3 Inhibitor ISM8969 Achieves First-in-Human Milestone in Phase I Trial for CNS Disorders
  • Hengrui Pharmaceuticals Expands Dalpiciclib Label with NMPA Approval for Early Breast Cancer Adjuvant Therapy
  • WuXi XDC Partners with BioDlink International for Monoclonal Antibody Intermediate Manufacturing in RMB 190 Million CRDMO Agreement
  • Hengrui Pharmaceuticals Receives NMPA Clinical Approvals for Two Novel Anti-Tumor Candidates SHR-6914 and HRS-7525, Addressing Unmet Needs in Prostate Cancer and Solid Tumors
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Walvax Biotechnology’s 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial

Company Drug

Insilico Medicine’s NLRP3 Inhibitor ISM8969 Achieves First-in-Human Milestone in Phase I Trial for CNS Disorders

Company Drug

Hengrui Pharmaceuticals Expands Dalpiciclib Label with NMPA Approval for Early Breast Cancer Adjuvant Therapy

Company Deals

WuXi XDC Partners with BioDlink International for Monoclonal Antibody Intermediate Manufacturing in RMB 190 Million CRDMO Agreement

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.